Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Introduction: mortality associated with patients with multiple myeloma (MM) is the only data available in Ecuador. This study aims to characterize the disease, determine its mortality rate and describe related factors in the cases of MM treated at the Carlos Andrade Marin Hospital. Materials and methods: retrospective analysis of demographic data, clinical characteristics of patients with MM, collected between january and december 2011. Results: 52 patients between 29 to 89 years (mean 61), 15 were women (29%). 73% had an IgG myeloma, 28% IgA and 19% were light chains. According to the staging system Durie and Salmon (D & S) 13% in stage I, stage II 25%, 33% stage III. 41% was excluded because information was not available. Mortality in the advanced clinical stage of myeloma (D & S stage III) was 10% in stages I and II were not registering deaths. Renal damage was more frequent in stage III (33%) compared with stages I (13%) and II (25%). Conclusions: mortality was associated with advanced stages of MM (stage III) and kidney damage present (29%).
REFERENCIAS BIBLIOGRÁFICAS
GLOBOCAN 2002 Project. International Agency for Research on Cancer, http://www-dep.iarc.fr/ [Consultado el 30 de marzo de 2006]
Estadísticas sanitarias mundiales 2011. Organización Mundial de la Salud, OMS; ISBN 978 92 4 356419 7, Francia, 2011
Guillermo Conté L1,7, Gastón Figueroa M1, Vivianne Lois V2, María Elena Cabrera C3, Alvaro León R4, Hernán García L5, Hernán Rojas R6. Mieloma múltiple en Chile. Características clínicas y sobrevida; Rev. méd. Chile v.135 n.9 Santiago sep. 2007
Kyle RA, Rajkumar SV. Multiple Myeloma. N Eng lJ Med 2004; 351: 1860-73
Epidemiología del Cáncer en Quito 2003 - 2005, Registro Nacional de Tumores Quito, SOLCA núcleo Quito, http://www.solcaquito.org.ec
Recursos y actividades de salud; INEC, Ecuador, 2012; http://www.inec.gob.ec/estadisticas
Dispenzieri A, Lacy M, Greipp P. Multiple Myeloma. En: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader BE (eds). Wintrobe’s Clinical Hematology, 11th Edition. Lippincot Williams and Wilkins, 2004; 2583-2636
Anderson KC, Pazdurn R, Farrell AT. Development of Effective New Treatments for Multiple Myeloma. J Clin Oncol 2005; 23:7207-11
Augustson BM, Begum G, Dunn J, Barth NJ, Davies F, Morgan G et al. Early Mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council Trials between 1980 and 2002 -Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219-26
Hungría VTM, Maiolino A, Martínez G, Coelho EOM, Bittencourt R, Souza CA et al. South american multiple myeloma study: Epidemiological and clinical characteristics of 751 patients. Haematologica 2005; SI: 120 (abstract po.521)
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57
Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-54
Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 2006; 42: 1671-83
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 15-17
Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127: 299-304
Blade J, Rosinol L. Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 635-52
Cesana C, Nosari AM, Klersy C, Miqueileiz S, Rossi V, Ferrando P et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine adriamycin dexamethasone schedules. Haematologica 2003; 88: 1022-8
Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996; 100: 624-8
Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG.
Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994; 343: 1059-63
San Miguel JF, García Sanz R. Prognostic features of multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 569-83
Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23: 6339-44
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-20
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.